Shopping Cart
- Remove All
Your shopping cart is currently empty
ACT-281959, a prodrug of ACT-246475, is a novel potent and selective P2Y12 Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel. ACT-281959 showed antithrombotic efficacy after oral administration in the rat ferric chloride model. ACT-281959 entered clinical studies in healthy volunteers.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $2,270 | 10-14 weeks | |
| 50 mg | $2,980 | 10-14 weeks | |
| 100 mg | $4,000 | 10-14 weeks |
| Description | ACT-281959, a prodrug of ACT-246475, is a novel potent and selective P2Y12 Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel. ACT-281959 showed antithrombotic efficacy after oral administration in the rat ferric chloride model. ACT-281959 entered clinical studies in healthy volunteers. |
| Molecular Weight | 850.85 |
| Formula | C38H55N6O14P |
| Cas No. | 1159501-31-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.